NASDAQ: AIMDAinos Inc Stock
$0.86+0.01 (+1.18%)
Updated May 31, 2024
AIMD Price
$0.86
Fair Value Price
N/A
Market Cap
$5.40M
52 Week Low
$0.79
52 Week High
$6.10
P/E
-0.26x
P/B
0.24x
P/S
-231.38x
PEG
N/A
Dividend Yield
N/A
Revenue
-$28.44k
Earnings
-$14.56M
Gross Margin
-160.6%
Operating Margin
50,573.13%
Profit Margin
51,221.7%
Debt to Equity
0.31
Operating Cash Flow
-$5M
Beta
83.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIMD Overview
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AIMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIMD is good value based on its book value relative to its share price (0.24x), compared to the US Medical Devices industry average (3.92x)
P/B vs Industry Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIMD due diligence checks available for Premium users.
Be the first to know about important AIMD news, forecast changes, insider trades & much more!
AIMD News
Valuation
AIMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
30.22x
Market
28.44x
AIMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
3.92x
AIMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIMD's financial health
Profit margin
Revenue
$20.7k
Net Income
-$3.3M
Profit Margin
-15,991.2%
AIMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$29.8M
Liabilities
$7.1M
Debt to equity
0.31
AIMD's short-term liabilities ($4.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIMD's long-term liabilities ($2.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
-$111.3k
Financing
$777.5k
AIMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIMD vs Medical Device Stocks
Ainos Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.